Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

461. Interferon beta treatment for multiple sclerosis (funded by DIHTA)

Interferon beta treatment for multiple sclerosis (funded by DIHTA) Interferon beta treatment for multiple sclerosis (funded by DIHTA) Interferon beta treatment for multiple sclerosis (funded by DIHTA) Danish Centre for Evaluation and Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Danish Centre for Evaluation (...) and Health Technology Assessment. Interferon beta treatment for multiple sclerosis (funded by DIHTA) Copenhagen: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). 1999 Authors' objectives This report aims to include: 1) an analysis of the experience of interferon beta treatment for relapsing multiple sclerosis (MS), and 2) an account of the consequences of a possible widening of the range of patients being offered this treatment to include patients with secondary progressive MS

1999 Health Technology Assessment (HTA) Database.

462. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis Forbes R B, Lees A, Waugh N, Swingler R J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Interferon beta for secondary progressive multiple sclerosis. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population consisted of patients with secondary progressive multiple sclerosis. Setting The study setting was a hospital (specialist outpatient clinic). The economic

1999 NHS Economic Evaluation Database.

463. Development of the protocol for the proposed trial of beta interferon in multiple sclerosis

Development of the protocol for the proposed trial of beta interferon in multiple sclerosis Development of the protocol for the proposed trial of beta interferon in multiple sclerosis Development of the protocol for the proposed trial of beta interferon in multiple sclerosis Rothwell P Citation Rothwell P. Development of the protocol for the proposed trial of beta interferon in multiple sclerosis. Health Technology Assessment Authors' conclusions Completed - No publication required in the HTA (...) monograph series. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Interferon-beta; Multiple Sclerosis; Randomized Controlled Trials as Topic Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32010000420 Date

1999 Health Technology Assessment (HTA) Database.

464. Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis

Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis Nicholson T, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Nicholson T, Milne R. Beta intererons (1a and 1b) in elapsing-remitting and secondary progressive multiple sclerosis. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1999 Authors' objectives This report considers the cost-effectiveness of the beta interferons (IFNB -1a and -1b) in the treatment of relapsing-remitting (RR) and IFNB-1b in the treatment of secondary progressive (SP) multiple sclerosis (MS). Authors' conclusions There is good evidence from

1999 Health Technology Assessment (HTA) Database.

465. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. (Abstract)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Previous trials of interferon beta in multiple sclerosis (MS) have shown efficacy, but the degree of clinical benefit remains uncertain, and the optimum dose is not known. We undertook a double-blind, placebo-controlled study in relapsing/remitting MS to investigate

1998 Lancet Controlled trial quality: predicted high

466. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. (Abstract)

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. The beneficial effects of interferon beta have only been shown for patients in the relapsing-remitting phase of multiple sclerosis (MS). The role of interferon beta in the treatment of patients who are in the secondary progressive phase of the disease (SP-MS), and for whom no effective drug

1998 Lancet Controlled trial quality: predicted high

467. A cost-utility analysis of interferon beta for multiple sclerosis

A cost-utility analysis of interferon beta for multiple sclerosis A cost-utility analysis of interferon beta for multiple sclerosis A cost-utility analysis of interferon beta for multiple sclerosis Parkin D, Miller P, McNamee P, Thomas S, Jacoby A, Bates D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology Use of interferon beta (IFNB-1b) for people with relapse-remitting multiple sclerosis (MS). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population Ambulant patients with relapse-remitting multiple sclerosis. Setting The practice setting was the community. The clinical trial was conducted in the USA and Canada. Economic analyses were carried out in the UK. Dates to which data relate

1998 NHS Economic Evaluation Database.

468. Cost-effectiveness of interferon beta for multiple sclerosis: the implications of new information on clinical effectiveness

Cost-effectiveness of interferon beta for multiple sclerosis: the implications of new information on clinical effectiveness Cost-effectiveness of interferon beta for multiple sclerosis: the implications of new information on clinical effectiveness Cost-effectiveness of interferon beta for multiple sclerosis: the implications of new information on clinical effectiveness McNamee P, Parkin D Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McNamee P, Parkin D. Cost-effectiveness of interferon beta for multiple sclerosis: the implications of new information on clinical effectiveness. Health Technology Assessment 1998; 2(4) Update 1999: 1-7 Authors' objectives This paper describes and updates a previous study which was funded by the NHS HTA programme to investigate the cost-effectiveness of interferon beta-1b for the treatment of RRMS

1998 Health Technology Assessment (HTA) Database.

469. A cost-utility analysis of interferon beta for multiple sclerosis

A cost-utility analysis of interferon beta for multiple sclerosis A cost-utility analysis of interferon beta for multiple sclerosis A cost-utility analysis of interferon beta for multiple sclerosis Parkin D, Miller P, McNamee P, Thomas S, Jacoby A, Bates D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Parkin D, Miller P, McNamee P (...) , Thomas S, Jacoby A, Bates D. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technology Assessment 1998; 2(4): 1-58 Authors' objectives 1. To identify to what extent IFBeta-1b generates quality of life (QOL) gains. 2. To measure and value QOL gains. 3. To assess the net costs to the health service and society associated with IFBeta-1b. 4. To compare net costs and QOL gains in a cost-utility model. Authors' conclusions IFBeta-1b produces important occasional short-term gains

1998 Health Technology Assessment (HTA) Database.

470. Comparison of drug treatments for multiple sclerosis - systematic review

Comparison of drug treatments for multiple sclerosis - systematic review Comparison of drug treatments for multiple sclerosis - systematic review Comparison of drug treatments for multiple sclerosis - systematic review Otten N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Otten N. Comparison of drug treatments for multiple sclerosis (...) USD) vs. 6 MIU (approximately 17,000 USD) is probably not justified. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Costs and Cost Analysis; Interferon-beta; Multiple Sclerosis /drug therapy Language Published English, French Country of organisation Canada Address for correspondence 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392; Email: jills@ccohta.ca AccessionNumber 31999008424 Date bibliographic record published 14/05/1999

1998 Health Technology Assessment (HTA) Database.

471. A cost-utility analysis of interferon beta for multiple sclerosis Full Text available with Trip Pro

A cost-utility analysis of interferon beta for multiple sclerosis A cost-utility analysis of interferon beta for multiple sclerosis Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata

1998 NIHR HTA programme

472. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. (Abstract)

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. An intravenous rather than oral course of methylprednisolone is often prescribed for treating acute relapses in multiple sclerosis (MS) despite the lack of evidence to support this route of administration. Our double-blind placebo-controlled randomised trial was designed to compare the efficacy of commonly used intravenous and oral steroid regimens in promoting recovery from acute relapses in MS

1997 Lancet Controlled trial quality: predicted high

473. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. (Abstract)

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Multiple sclerosis is an autoimmune disorder characterised by the repeated occurrence of demyelinating lesions within the central nervous system. Uncontrolled studies and experimental evidence suggest beneficial effects of repeated administration of intravenous immunoglobulin (IVIg) by immunomodulating mechanisms (...) and induction or remyelination. We aimed to investigate the efficacy of IVIg in a randomised double-blind multicentre study.Patients with relapsing-remitting multiple sclerosis were randomly assigned a monthly dose of IVIg (0.15-0.2 g/kg bodyweight) or placebo. Duration of treatment was 2 years. The primary outcome measures were the effect of treatment on clinical disability-measured by the absolute change in Kurtzke's expanded disability status scale (EDSS) score- and the proportion of patients

1997 Lancet Controlled trial quality: predicted high

474. Interferon beta-1a in relapsing-remitting multiple sclerosis

Interferon beta-1a in relapsing-remitting multiple sclerosis Interferon beta-1a in relapsing-remitting multiple sclerosis Interferon beta-1a in relapsing-remitting multiple sclerosis Nicholson T, Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nicholson T, Stein K. Interferon beta-1a in relapsing-remitting multiple sclerosis (...) . Southampton: Wessex Institute for Health Research and Development (WIHRD) 1997 Authors' objectives The authors consider the cost-effectiveness of interferon beta-1a (IFNB-1a) in the treatment of relapsing-remitting multiple sclerosis (MS) compared with placebo, and review the evidence for interferon beta-1b (IFNB-1b). Authors' conclusions The authors found the data inconclusive. They found the evidence for IFNB-1a inadequate owing to methodological limitations of the trial, and state that since trial

1997 Health Technology Assessment (HTA) Database.

475. Does a placebo-effect exist in clinical trials on multiple sclerosis: review of the literature

Does a placebo-effect exist in clinical trials on multiple sclerosis: review of the literature Does a placebo-effect exist in clinical trials on multiple sclerosis: review of the literature Does a placebo-effect exist in clinical trials on multiple sclerosis: review of the literature La Mantia L, Eoli M, Salmaggi A, Milanese C Authors' objectives To verify whether the outcome in placebo-treated multiple sclerosis (MS) patients corresponds to that expected on the basis of the natural history (...) comparability between the studies. Bibliographic details La Mantia L, Eoli M, Salmaggi A, Milanese C. Does a placebo-effect exist in clinical trials on multiple sclerosis: review of the literature. Italian Journal of Neurological Sciences 1996; 17(2): 135-139 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Clinical Trials as Topic /methods; Humans; Multiple Sclerosis /drug therapy; Placebo Effect; Prognosis AccessionNumber 11997008421 Date bibliographic record published 31/03/2000 Date

1996 DARE.

476. Copolymer 1 in relapsing-remitting multiple sclerosis

Copolymer 1 in relapsing-remitting multiple sclerosis Copolymer 1 in relapsing-remitting multiple sclerosis Copolymer 1 in relapsing-remitting multiple sclerosis Nicholson T, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nicholson T, Milne R. Copolymer 1 in relapsing-remitting multiple sclerosis. Southampton: Wessex Institute (...) for Health Research and Development (WIHRD) 1996 Authors' objectives The authors aim to evaluate the efficacy of copolymer 1 in the treatment of relapsing-remitting multiple sclerosis (MS) compared with no treatment in the progression of the disease. Authors' conclusions The authors conclude that copolymer 1 is an expensive drug with small quantifiable benefits in terms of QALYs, and are unconvinced about the merits of introducing it. Project page URL Indexing Status Subject indexing assigned by CRD MeSH

1996 Health Technology Assessment (HTA) Database.

477. Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis

Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis Vamvakas E C, Pineda A A, Weinshenker B G Authors' objectives To examine the hypothesis that the addition (...) of therapeutic plasma exchange (TPEX) to an immunosuppressive regime increases the regimes efficacy to halt the progression of chronic multiple sclerosis (MS). Searching MEDLINE was searched from January 1980 to June 1994 for relevant articles published in English, French and Spanish. The bibliographies of retrieved articles were examined for further studies. Study selection Study designs of evaluations included in the review Clinical trials were included if they were prospective and compared treatment

1995 DARE.

478. Cladribine in treatment of chronic progressive multiple sclerosis. (Abstract)

Cladribine in treatment of chronic progressive multiple sclerosis. Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role. The nucleoside drug cladribine is a potent lympholytic agent with few side-effects. We have studied its efficacy and safety in a randomised double-blind trial. 51 patients (48 entered as matched pairs) received four monthly courses of 0.7 mg/kg cladribine or placebo (saline) given

1994 Lancet Controlled trial quality: uncertain

479. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. (Abstract)

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. Optic neuritis is often the first clinical manifestation of multiple sclerosis, but little is known about the effect of corticosteroid treatment for optic neuritis on the subsequent risk of multiple sclerosis.We conducted a multicenter study in which 389 patients with acute optic neuritis (and without known multiple sclerosis) were randomly assigned (...) to receive intravenous methylprednisolone (250 mg every six hours) for 3 days followed by oral prednisone (1 mg per kilogram of body weight) for 11 days, oral prednisone (1 mg per kilogram) alone for 14 days, or placebo for 14 days. Neurologic status was assessed over a period of two to four years. The patients in the first group were hospitalized for three days; the others were treated as outpatients.Definite multiple sclerosis developed within the first two years in 7.5 percent of the intravenous

1993 NEJM Controlled trial quality: predicted high

480. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. (Abstract)

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. To find out whether non-specific immunosuppression is beneficial in multiple sclerosis (MS) a randomised, placebo-controlled, single-masked trial was carried out in nine university centres. 168 patients with clinically or laboratory-supported definite MS in progressive phase (deterioration by at least 1.0 on the expanded disability

1991 Lancet Controlled trial quality: uncertain